Biotest AG / Key word(s): Change of Personnel 09.07.2014 18:12 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- / Ad-hoc RELEASE Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG) Dr. Bernhard Ehmer to become new CEO of Biotest AG Dreieich, 9 July 2014 - The Supervisory Board of Biotest AG, in its meeting today, has appointed Dr. Bernhard Ehmer (59) as member of the Executive Board effective November 1st, 2014. As of January 1st, 2015, Ehmer will take over the role as CEO from Prof. Dr. Gregor Schulz (64) whose appointment will then end after twelve years due to reaching the age limit. Bernhard Ehmer got a PhD in Medicine and was resident in internal medicine at a teaching hospital of the University of Heidelberg before he started his career in the pharmaceutical industry first with Boehringer Mannheim, then with Merck KGaA. Later he was CEO of Fresenius Biotech GmbH before he joined Imclone Systems Corp. In his last position as CEO & President of Imclone Systems Corp. his focus has been the successful clinical development and market preparation of biologic pharmaceuticals. Finally he successfully integrated most of the key functions of Imclone Systems into the organization of Eli Lilly, the parent company of Imclone Systems. Besides Dr. Bernhard Ehmer as CEO, Dr. Michael Ramroth (CFO) and Dr. Georg FloÃ, (COO) will continue to be members of the Executive Board of Biotest AG. Biotest Aktiengesellschaft The Executive Management Board Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.de About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.000 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange. Securities' ID No., ISIN ordinary shares: 522720, DE0005227201 Securities' ID No., ISIN preference shares: 522723, DE0005227235 Listing: Prime Standard Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart 09.07.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Biotest AG LandsteinerstraÃe 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Biotest AG: Dr. Bernhard Ehmer to become new CEO of Biotest AG
| Source: EQS Group AG